Detection of tumor recurrence using technetium99m-tetrofosmin brain SPECT in patients with previously irradiated brain tumors
Keywords:
radiotherapy, brain neoplasms, radionecrosis, tomography, emission-computed, singlephotonAbstract
Objective: To assess the clinical utility of brain SPECT with Tc-99m Tetrofosmin to differentiate between tumor recurrence and radionecrosis in patients with primary brain tumors previously treated with external beam radiotherapy.
Materials and methods: Thirteen patients with clinical or radiological suspicion of tumor recurrence were studied with brain SPECT using 20 mCi of Tc-99m Tetrofosmin. Obtained images were interpreted by consensus between two experienced observers and subsequently classified as positive or negative for tumor viability. Results were compared to those of conventional diagnostic imaging techniques. Diagnostic test values and 95% confidence intervals were quantified.
Results: SPECT results included 7 true-positives, 5 true-negatives and 1 false negative result.
Conclusions: Tc-99m Tetrofosmin brain SPECT night be a useful alternative to diagnose recurrent brain tumors, especially with non-conclusive clinical and radiological findings.
Author Biographies
Augusto Llamas, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología E.S.E., Grupo de Medicina Nuclear, Bogotá, D.C., Colombia
Amelia de los Reyes, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología E.S.E., Grupo de Medicina Nuclear, Bogotá, D.C., Colombia
Luz Faride Uribe, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología E.S.E., Grupo de Medicina Nuclear, Bogotá, D.C., Colombia
Teresa Martínez, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología E.S.E., Grupo de Investigación Epidemiológica, Bogotá, D.C., Colombia
References
Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 1995; 36(1): 159-64.
Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000; 41(11): 1861-7.
Mountz JM, Deutsch G, Kuzniecky R, Rosenfeld SS. Brain SPECT: 1994 update. En: Freeman LM, ed. Nuclear Medicine Annual. New York: Raven Press; 1994.p.1-54. https://doi.org/10.1111/jon19955154a
Davis WK, Boyko QB, Hoffman JM Hanson MW, Scholdsc, et al. (18F) 2-fluoro-2-deoxyglucose positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia, AJNR Am J Neuroradiol 1993; 14(3): 515-23.
Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, et al. Brain radiation lesions: MR imaging. Radiology 1986; 158(1): 149-55. https://doi.org/10.1148/radiology.158.1.3940373
Nelson DR, Yuh WT, Wen BC, Ryals TJ, Cornell SH. Cerebral necrosis simulating an intraparenchymal tumor, AJNR Am J Neuroradiol 1990; 11(1); 211- 2.
Nelson SJ, Huhns S, Vigneron DB, Day MR, Wardll, et al. Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: Presentation of a detailed case study. J Magn Reson Imaging 1997; 7(6): 1146-52. https://doi.org/10.1002/jmri.1880070630
Byrne TN. Imaging of gliomas. Semin Oncol 1994; 21(2): 162-71.
Soler C, Beauchesne P, Maatougui K, Scmitt T, Barral FG, et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998; 25(12): 1649-57. https://doi.org/10.1007/s002590050344
Lorberboym M, Mandell L, Mosesson RE, Germano I, Lou W. et al. The role of Thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 1997; 38(2): 223-6.
Kline JL, Noto RB, Glantz M. Single-photon emission CT in the evaluation of recurrent brain tumor in patients treated with gamma knife radiosurgery or conventional radiation therapy, AJNR Am J Neuroradiol 1996; 17(9): 1681-6.
Maffioli L, Gasparini M, Chiti A, Gramaglia A, Mongioj V, et al. Clinical role of technetium-99 single-photon emission tomography sestamibi in evaluating pretreated patients with brain tumors. Eur J Nucl Med 1996; 23(3): 308-11. https://doi.org/10.1007/BF00837629
Soricelli A, Cuocolo A, Varrone A, Discepolo A, Tedeschi E, et al. technetium 99m-tetrofosmin uptake In brain tumours by SPECT: Comparison with 201 imaging. J Nucl Med 1998; 39(5): 802-6.
Kostakoglu L, Uzal D, Gülaldi N, Uysal U, Caner B, et al. Detection of residual malignant brain tumors using technetium 99m-tetrofosmin. Eur J Nucl Med 1995; 22: 867.
Scopinaro F, De Vicentis G, Raffetto N, Ierardi M, Ghaffar GDj, et al. SPECT images of astrocytoma with 99mTc-MIBI and 99mTc-tetrofosmin. Eur J Nucl Med 1995; 22: 867.
Choi JY, Kim SE, Shin HJ, Kim BT, Kim JH. Brain tumor imaging with 99mTc-tetrofosmin: Comparison with Tl-201,99mTc-MIB I and 18F-fluorodeoxyglucose. J Neurooncol 2000; 46(1): 63-70. https://doi.org/10.1023/A:1006391701818
Pauwels EK, McCready VR, Stoot JH, Van Deurzen DF. The mechanism of accumulation of tumourlocalising radiopharmaceuticals. Eur J Nucl Med 1998; 25(3): 277-305. https://doi.org/10.1007/s002590050229
Schomacker K, Schicha H. Use of myocardial imaging agents for tumour diagnosis_a success story? Eur J Nucl Med 2000; 27(12): 1845-63. https://doi.org/10.1007/s002590000379
Mansi L, Rambaldi PF, Procaccini E, Di Gregorio FD, Laprovitera A, Pecori B et al. Scintimammography with 99mTc-tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 1996; 23(8): 932-9. https://doi.org/10.1007/BF01084367
Llamas Olier A, De los Reyes A, Martínez MC, Terselich G, Suárez A. 99mTc-tetrofosmin uptake in osteogenic sarcomas predicts therapeutic response and clinical outcome. Eur J Nucl Med 1998; 25: 1055.
Basoglu T, Sahin M, Coskun C, Koparan A, Bernay I, Erkan L. Technetium-99m-tetrofosmin uptake in malignant lung tumors. Eur J Nucl Med 1995; 22(7): 687-9. https://doi.org/10.1007/BF01254572
OTuama LA, Treves ST, Larar JN, Packard AB, Kwan AJ, Barnes PD et al. Tl-201 versus 99mTc- MIBI SPECT in evaluation of childhood brain tumors: A within-subject comparison. J Nucl Med 1993; 34(6): 1045-51.
Dierckx RA, Martin JJ, Dobbeleir A, Crols R, Neetens I, De Deyn PP. Sensitivity and specificity of thallium-20/single-photn emission tomography in the functional detection and differential diagnosis o f brain tumours. Eur J Nucl Med 1994; 21(7): 621-33. https://doi.org/10.1007/BF00285584
Macapinlac H, Scott A, Caluser C. Comparison of Tl- 201 and 99mTc-sestamibi with mr i in the evaluation of recurrent brain tumors. J Nucl Med 1992; 33: 867.
Black KL, Hawkins RA, Kim KT, Becker DP, Lemer C, Marciano D. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989; 71(3): 342-6. https://doi.org/10.3171/jns.1989.71.3.0342
Staundenherz A, Fazeny B, Marosi C, Nasel C, Hoffmann M, Puig S et al. Does 99mTc-sestamibi in high-grade malignant brain tumors reflect blood-brain barrier damage only? Neuroimage 2000; 12:109-111. https://doi.org/10.1006/nimg.2000.0594
Abdel-Dayem HM. Tl-201-chloride uptake ratios in differentiating benign from malignant lesions: Recommendations for ratio calculations and interpretation. Nucl Med Commun 1995; 16: 145-149. https://doi.org/10.1097/00006231-199516030-00006
Valdés Olmos RA, Hoefnagel CA, Van der Schoot JB. Nuclear medicine in the monitoring of organ function and the detection of injury related to cancer therapy. Eur J Nucl Med 1993; 20(6): 515-46. https://doi.org/10.1007/BF00175165
Kim KT, Black KL, Marciano D, Mazziotta JC, Guze BH, Grafton S et al. Thalliuml-201 SPECT imaging of brain tumors: Methods and results. J Nucl Med 1990; 31(6): 965-9.
Goethals I, De Winter O, Dierckx R, Annovazzi A, Signore A, Van de Wiele C. False-negative 99mTc-MIBI scintigraphy in histopathologically proved recurrent high-grade oligodendroglioma. Clin Nucl Med 2003; 28(4): 299-301. https://doi.org/10.1097/01.RLU.0000057555.93082.B5
Kaplan WD, Takronan T, Moms JH, Rumbaugh CL, Connolly BT, Atkins HL. Thallium-201 brain tumor imaging: A comparative study with pathologic correlation. J Nucl Med 1987; 28(1): 47-52.
Vertosick FT Jr, Selker RG, Grossman SJ, Joyce JM. Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with multiform glioblastoma. Neurosurgery 1994; 34(3): 396-401. https://doi.org/10.1227/00006123-199403000-00002
Bagni B, Pinna L, Tamarozzi R, Cattaruzzi E, Marzola MC, Bagni I et al. SPECT imaging of intracranial tumours with 99Tcm-sestamibi. Nucl Med Commun 1995; 16(4): 258-64. https://doi.org/10.1097/00006231-199504000-00157
Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant p-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53(5): 977-84.
Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99mtetrofosmin as a substrate for p-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996; 37(9): 1578-82.
Yokogami K, Kawano H, Moriyama T, Uehara H, Sameshima T, Oku T et al. Application of SPECT using 99mTc-sestamibi in brain tumours and comparison with expresssion of the MDR-1 gene: Is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPECT? Eur J Nucl Med 1998; 25(4): 401-9. https://doi.org/10.1007/s002590050238
Leeds NE. Pitfalls recognized in the magnetic resonance evaluation of patients with primary and secondary brain neoplasms. Neuroimaging Clin N Am 1993; 3: 755-770.
Di Chiro G, Fulham MJ. Virchow's shackles: Can PET-FDG challenge tumor histology? AJNR Am J Neuroradiol 1993; 14(3): 524-7.
Sackett DL, Haynes RB, Guyatt GH et al. Selección de pruebas diagnósticas. En: Sackett DL, Haynes RB, Guyatt GH, Tugwell P, eds. Epidemiología clínica. Ciencia básica para la medicina clínica. 2a ed. Buenos Aires: Editorial Médica Panamericana; 1994.p.62-78.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
